222 related articles for article (PubMed ID: 31364863)
21. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
[TBL] [Abstract][Full Text] [Related]
22. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
.
Yamada Y; Ueno T; Irifuku T; Nakashima A; Doi S; Ichinohe T; Masaki T
Clin Nephrol; 2018 Sep; 90(3):232-236. PubMed ID: 29701172
[TBL] [Abstract][Full Text] [Related]
23. Castleman Disease.
Wang W; Medeiros LJ
Surg Pathol Clin; 2019 Sep; 12(3):849-863. PubMed ID: 31352991
[TBL] [Abstract][Full Text] [Related]
24. Use of a claims database to characterize and estimate the incidence rate for Castleman disease.
Munshi N; Mehra M; van de Velde H; Desai A; Potluri R; Vermeulen J
Leuk Lymphoma; 2015 May; 56(5):1252-60. PubMed ID: 25120049
[TBL] [Abstract][Full Text] [Related]
25. Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital.
Luo JM; Li S; Huang H; Cao J; Xu K; Bi YL; Feng RE; Huang C; Qin YZ; Xu ZJ; Xiao Y
BMC Pulm Med; 2015 Apr; 15():34. PubMed ID: 25886851
[TBL] [Abstract][Full Text] [Related]
26. Recent Advances in Castleman Disease.
Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
[TBL] [Abstract][Full Text] [Related]
27. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.
Bowne WB; Lewis JJ; Filippa DA; Niesvizky R; Brooks AD; Burt ME; Brennan MF
Cancer; 1999 Feb; 85(3):706-17. PubMed ID: 10091744
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Features and Prognosis of Patients with Castleman's Disease].
Huang XJ; Zhang XL; Wei XF; Liang XQ; Fu Y; Zhao YY; Li QF; Zhang QK; Feng YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):135-140. PubMed ID: 36765490
[TBL] [Abstract][Full Text] [Related]
29. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.
Ogita M; Hoshino J; Sogawa Y; Sawa N; Katori H; Takemoto F; Ubara Y; Hara S; Miyakoshi S; Takaichi K
Clin Nephrol; 2007 Sep; 68(3):171-6. PubMed ID: 17915620
[TBL] [Abstract][Full Text] [Related]
30. Hyaline Vascular Type of Unicentric Castleman Disease in a Kidney with End-Stage Renal Disease: A Case Report of a Rare Entity at an Unusual Location and a Special Clinical Setting.
Chen CH; Li HN
Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36428938
[TBL] [Abstract][Full Text] [Related]
31. The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features.
Pelliccia S; Rogges E; Cardoni A; Lopez G; Conte E; Faccini AL; De Vito R; Girardi K; Bianchi A; Annibali O; Fratoni S; Remotti D; De Angelis G; Giordano C; Palumbo G; Scarpino S; Del Porto F; Bianchi MP; Di Gregorio F; Tafuri A; Di Napoli A
Br J Haematol; 2024 Feb; 204(2):534-547. PubMed ID: 37953489
[TBL] [Abstract][Full Text] [Related]
32. [Not Available].
Bertinchamp R; Terriou L
Rev Med Interne; 2022 Dec; 43(10S1):10S4-10S9. PubMed ID: 36657941
[TBL] [Abstract][Full Text] [Related]
33. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
34. Castleman disease: Experience from a single institution.
Abraham SS; Narayanan G; Thambi SM; Vasudevan JA; Joy Philip DS; Purushothaman PN; Nair SG; Nair R
Med Int (Lond); 2023; 3(6):56. PubMed ID: 37927353
[TBL] [Abstract][Full Text] [Related]
35. Retrospective cohort evaluation of non-HIV Castleman disease from a single academic center in Beijing, China.
Guo M; Nong L; Wang M; Zhang Y; Wang L; Sun Y; Wang Q; Liu H; Ou J; Cen X; Ren H; Dong Y
Ann Hematol; 2024 Jan; 103(1):153-162. PubMed ID: 37749319
[TBL] [Abstract][Full Text] [Related]
36. Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
Melikyan AL; Egorova EK; Julhakyan HL; Kovrigina AL; Savchenko VG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S159-65. PubMed ID: 27133959
[TBL] [Abstract][Full Text] [Related]
37. Clinical and histopathology characteristics of Castleman disease: a multicenter study of 51 Brazilian patients.
Leite JM; Barrese TZ; Sementilli L; de Freitas LLL; do Espirito Santo KS; Delamain MT; Baiocchi OCCG; Brasil SAB; Chiattone CS
Ann Hematol; 2023 May; 102(5):1121-1129. PubMed ID: 36763110
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology of Castleman Disease.
Simpson D
Hematol Oncol Clin North Am; 2018 Feb; 32(1):1-10. PubMed ID: 29157611
[TBL] [Abstract][Full Text] [Related]
39. Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan.
Masaki Y; Kawabata H; Fujimoto S; Kawano M; Iwaki N; Kotani T; Nakashima A; Kurose N; Takai K; Suzuki R; Aoki S
J Clin Exp Hematop; 2019 Dec; 59(4):175-178. PubMed ID: 31708515
[TBL] [Abstract][Full Text] [Related]
40. Long-term treatment outcome of Castleman's disease: A real-world experience.
Min GJ; Jeon YW; Kim TY; Kwag DH; Lee JH; Lee JY; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Cho SG
Front Oncol; 2022; 12():974770. PubMed ID: 35992883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
